EP1781230A1 - Système d'emballage à dose variable - Google Patents

Système d'emballage à dose variable

Info

Publication number
EP1781230A1
EP1781230A1 EP05789206A EP05789206A EP1781230A1 EP 1781230 A1 EP1781230 A1 EP 1781230A1 EP 05789206 A EP05789206 A EP 05789206A EP 05789206 A EP05789206 A EP 05789206A EP 1781230 A1 EP1781230 A1 EP 1781230A1
Authority
EP
European Patent Office
Prior art keywords
formulation
package
unit dosage
subunit
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05789206A
Other languages
German (de)
English (en)
Inventor
Shirishkumar B. Kulkarni
Hemanshu S. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix AG
Original Assignee
Agennix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix AG filed Critical Agennix AG
Publication of EP1781230A1 publication Critical patent/EP1781230A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers

Definitions

  • This invention relates to a variable-dose packaging system.
  • Control of dosage delivery is essential for patients in order that they receive the required quantity of medication at specified time intervals as is best suited to the individual based upon parameters such as body surface area (bsa). This is particularly important in the case of high potency drugs or those with a narrow therapeutic index, the potential adverse outcomes resulting from improper dosage consumption of which could substantially harm the patient. A patient who receives an excess of a high potency drug or those with a narrow therapeutic index could suffer from serious side effects or even death. Conversely, a patient receiving an insufficient amount of such a drug will not experience the therapeutic benefits desired. It is usual in the art to address the issue of delivery of the required dose by providing the same active pharmaceutical agent in several different dosage strengths.
  • Synthroid® (levothyroxine sodium) is a synthetic thyroid hormone prescribed to patients with hypothyroidism and pituitary TSH suppression, as well being used to treat benign thyroid nodules and in conjunction with surgery and radioactive iodine therapy in the management of certain types of thyroid cancer.
  • Synthroid® (levothyroxine sodium) is presented in multiple dosage formulations including 25 meg, 50 meg, 75 meg, 88 meg, 100 meg, 112 meg, 125 meg, 137 meg, 150 meg, 175 meg, 200 meg and 300 meg (microgram) tablets.
  • Coumadin® is an anticoagulant used to treat acute pulmonary embolism, atrial fibrillation, and deep vein thrombosis, as well as to prevent clotting after heart valve replacement, and to prevent a recurrence of heart attack or stroke.
  • Coumadin® (warfarin) is available in numerous dosage formulations including 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 7.5 mg, and 10 mg tablets.
  • the costs and difficulties incurred in manufacturing such a number of different dosage-forms of these drugs,, together with the significant potential for confusion of physicians, pharmacists, caregivers or patients by the various different strengths, are examples of the limitations and potential disadvantages of such a solution.
  • Oncology drugs are generally considered high-potency therapeutic agents, for which a careful dosage is required, often customized to a particular patient depending on the patient's size, weight, age, condition, sex or other factors.
  • oral oncology drugs currently on the market.
  • none of them are currently available in packaging that is convenient and safe for the patient.
  • Xeloda® (capecitabine) is prescribed in 500 mg and 150 mg tablets, and is packaged in two separate bottles by dosage. The patient is prescribed a specific dose by the physician, which requires the patient to ingest the requisite combination of 500 mg and 150 mg tablets in order to achieve the prescribed dose.
  • Such advantages include those that may be provided by a package that allows multiple combinations of dosage levels to be achieved using a smaller number of standard units, a package that is safer for the patent or prescribing pharmacist, or a package that is easier for the patient to appropriately follow the therapeutic regimen.
  • a package that allows multiple combinations of dosage levels to be achieved using a smaller number of standard units a package that is safer for the patent or prescribing pharmacist, or a package that is easier for the patient to appropriately follow the therapeutic regimen.
  • such an invention may provide a prescription package to aid an elderly prostate cancer patient to take the correct dose of powerful anti-cancer pills, and hence increase their chance of successful treatment or an increase in their quality of life.
  • the invention relates to packages that facilitate tailoring the administration of a drug to a particular patient or treatment regimen.
  • the invention relates to a package for providing a customized dose of a variable-dose therapeutic regimen, comprising
  • the invention further relates to a kit for assembling or preparing a customized dosage of a variable-dose therapeutic regimen, comprising
  • (c) means to interconnect or physically associate the unit dosage forms of formulation A in a subunit A or the unit dosage forms of formulation B in a subunit B; wherein, formulation A and formulation B are different, and said customized dose is provided in a package.
  • each unit dosage form is enclosed in a rupturable cell.
  • each unit dosage form is enclosed in a blister pack or a foil pack.
  • each unit dosage form is enclosed in a blister pack.
  • a subunit is a strip of blister packs, wherein each blister pack contains a single unit dosage form.
  • each subunit contains a plurality of unit dosage forms, wherein the number of unit dosage forms in each subunit may be equal or unequal to the number of unit dosage forms in any other subunit in the package or kit in order to achieve either consistent or tapered dosing, respectively. In preferred embodiments, the number of unit dosage forms in each subunit is equal.
  • At least one subunit A is physically associated with at least one subunit B.
  • the unit dosage forms of formulation A and unit dosage forms of formulation B are arranged in a grid pattern such that each row is a dose and each column is a subunit.
  • the total number of doses in a kit or package is between 3 and 35, more preferably between 5 and 14, even more preferably about 14, about 7, or about 5. In a most preferred embodiment, the total number of doses in a kit or package is about 5.
  • Each dose may be designated with a day of the week or month, though not necessarily labeled with consecutive days.
  • the package or kit provides a customized dose of an orally available platinum complex, such as satraplatin.
  • a kit or package of the invention may include means to physically associate at least one subunit A with at least one subunit B or unit dosage forms of formulation A with formulation B.
  • means to physically associate subunit A with subunit B or unit dosage forms of formulation A with formulation B comprises positioning means.
  • the positioning means is a template or frame and one or more compartments, locations, adhesive positions, or slots adapted to receive an appropriate number of subunits A or B or unit dosage forms of formulation A or B.
  • the positioning means may be partially filled with a predefined set of subunits A or B or unit dosage forms of formulation A or B.
  • means to physically associate at least one subunit A with at least one subunit B comprises appendages on subunit A that are adapted to be put through receptacles of subunit B.
  • means to physically associate at least one subunit A with at least one subunit B comprises an adhesive unit region on subunit A that is adapted to adhere to subunit B.
  • the means to physically associate subunit A with subunit B comprises positioning means, such as a template and one or more compartments, locations, clips, fastenings, sockets, adhesive positions or slots adapted to receive an appropriate number of subunits A or B.
  • each dose is individually removable from the kit or package.
  • the kit or package further comprises instructions for a patient to consume a unit dosage form from each of subunit(s) A and B of the kit or package at predetermined intervals.
  • the instructions may or may not require the simultaneous or sequential consumption of unit dosage forms of formulations A and B.
  • the kit or package further comprises a plurality of unit dosage forms of formulation C, wherein formulation C is different from each of formulations A and B.
  • the unit dosage forms of A, the unit dosage forms of B, and the unit dosage forms of C together are arranged in a grid pattern where each row is a dose and each column is a subunit.
  • formulation A, formulation B, and formulation C each comprise an active ingredient X, and the amount of active ingredient X in the unit dosage forms of each formulation A, B, and C, is different from the amount of active ingredient X in the unit dosage forms of either of the other two formulations.
  • the kit or package further comprises instructions for a patient to consume a unit dosage form from each subunits C.
  • the invention further relates to a method to assemble or prepare a package of the invention.
  • the invention relates to a method of treating a patient suffering from a disease by administering or dispensing a package or kit of the invention.
  • Figure Ia shows a constant dose rectangular package according to an embodiment of the invention, wherein subunits (1 and 2; shaded) are columns, doses (3; dot pattern) are rows, and each subunit comprises unit dosage forms of formulation A 4 or B 5.
  • Figure Ib shows a tapered dose rectangular package according to an embodiment of the invention, wherein subunits (1 and 2; shaded) are columns, doses (3; dot pattern) are rows, and each subunit comprises unit dosage forms of formulation A 4 or B 5.
  • Figure 2 shows a circular package according to an embodiment of the invention, wherein subunits (1 and 2; shaded) are concentric rings, doses (3; dot pattern) are radii, and each subunit comprises unit dosage forms of formulation A 4 or B 5.
  • Figure 3 shows a rectangular kit according to an embodiment of the invention, wherein serially connected subunits A 1 are integral to the package and are serially associated with a series of compartments 6 that are adapted to each receive a subunit B 2.
  • Figure 4 shows a rectangular kit according to an embodiment of the invention, comprising serially connected compartments 6 which are adapted to each receive a subunit A 1 or B 2.
  • Figure 5 shows a rectangular package according to an embodiment of the invention, wherein the packaging surrounding each unit dosage form is perforated or scored 9 such that each subunit A 1 or B 2 and each dose 3 is individually removable from the package.
  • Figure 6 shows a rectangular kit according to an embodiment of the invention, wherein subunits A are serially connected and are equipped with holes 11 in the terminal subunit A 1.
  • Subunit B 2 is equipped with hooks 12 that are adapted to fit through the holes 11.
  • Figure 7 shows a rectangular kit according to an embodiment of the invention, wherein subunits A are serially connected and are equipped with slits 13 in the terminal subunit A 1.
  • Subunit B 2 is equipped with tabs 14 that are adapted to fit through the slits 13.
  • Figure 8 shows a rectangular kit according to an embodiment of the invention, wherein subunits A lare serially connected and are equipped with wells 15 in the terminal subunit A 1.
  • Subunit B 2 is equipped with plugs 16 that are adapted to couple with the wells 15.
  • Figure 9 shows a rectangular kit, wherein subunits A 1 are serially connected and are equipped with an adhesive strip 17 on the terminal subunit A 1.
  • Subunit B 2 is equipped with a strip of material 18 that is adapted to be adhered to the adhesive strip 17.
  • Figure 10 shows a rectangular Mt, wherein subunits A 1 and subunits B 2 are each equipped with protrusions 19 such that subunit(s) A 1 and subunit(s) B 2 can be associated in the same manner as a jigsaw puzzle.
  • Figure 11 shows subunits supplied as a roll of unit dosage forms.
  • Figure 12 shows subunits supplied as a sheet of unit dosage forms.
  • Figure 13 shows subunits supplied as concentric ring comprising unit dosage forms.
  • Figure 14 shows subunits supplied as strips.
  • the invention relates to packages and kits that facilitate tailoring the administration of a drug to a particular patient or treatment regimen.
  • the invention provides kits and packages for associating unit dosage forms of at least two different pharmaceutical formulations for convenient and regimented administration of the two formulations.
  • the differing formulations can be formulations that comprise different active ingredients, formulations that comprise the same active ingredient in different amounts (such as a low-dosage form and a high-dosage form), formulations that have different release characteristics (such as an immediate-release form and a slow release form), or any combination of these or other differences of formulation.
  • At least one of the unit dosage forms used in the various embodiments disclosed herein are orally administrable forms, such as tablets, gelcaps, and capsules, although any other unit dosage forms may be used without departing from the spirit of the invention disclosed herein.
  • the different formulations are presented in dosage forms that are different from each other.
  • the package may be rectangular.
  • the package shown comprises a plurality of subunits A 1 and a plurality of subunits B 2, which appear in Figure Ia as columns.
  • Each subunit comprises a plurality of interconnected unit dosage forms of formulation A 4 or formulation B 5, such that the unit dosage forms are arranged in a grid, and the unit dosage forms within each subunit are preferably identical, i.e., all unit dosage forms included in any particular subunit are interchangeable with and identical to the other unit dosage forms in that subunit, although they may be different from the unit dosage forms in other subunits within the package.
  • the subunits that form part of the package or kit may have pre ⁇ formed interconnections of any or all of the formulations, or may be formed by the means to physically associate the formulations.
  • the unit dosage forms are enclosed in rupturable cells.
  • Such rupturable cells may contain one or more unit dosage forms.
  • each unit dosage form is enclosed in a rupturable cell.
  • each unit dosage form is enclosed in a blister pack, a foil pack, a card package, wrapper, or sachet.
  • the multiple subunits are serially connected, such that each row is a dose 3.
  • the doses, too, are serially connected, so a patient can easily take a dose of medication by consuming all the unit dosage forms present in that row, without needing to assess how many unit dosage forms of a particular formulation are to be taken at that time.
  • the package is laid out so that the dose to be taken at a particular time is predetermined, and the patient need only follow basic instructions to take the correct amount of the medication in the package at the predetermined time.
  • the subunits that form part of the package or kit may be pre ⁇ formed interconnections of any or all of the unit dosage forms, or may be formed by the means to physically associate the formulations.
  • individual unit dosage-forms of formulation A and/or B may be placed into a preformed paperboard blanks such as described in US 5,954,202; by so doing, forming the subunits, the doses and a package of the instant invention.
  • Formulation A and formulation B each comprise an active ingredient, which may be the same or different.
  • both formulation A and formulation B comprise active ingredient X, wherein formulation A and formulation B have different pharmacological or pharmacokinetic properties, for example, formulation A may be a sustained release formulation when formulation B is a rapid release formulation, or the amount of active ingredient X in formulation A may be unequal to the amount of active ingredient X in formulation B.
  • the amount of active ingredient X in formulation A is greater than the amount of active ingredient X in formulation B (or vice versa) by a factor of about 2, about 4, about 5, about 10, about 25, about 50, or greater.
  • active ingredient X is selected from a cytotoxic compound, a chemotherapeutie compound, a high potency compound, a compound with a narrow therapeutic index, and an orally available platinum complex.
  • active ingredient X is satraplatin or a prodrug or metabolite thereof, wherein formulation A comprises 10-100 mg, preferably 25-75 mg, or most preferably about 50 mg of active ingredient X and formulation B comprises 1-20 mg, 5-15 mg, or most preferably about 10 mg of active ingredient X.
  • the unit dosage form of formulation A may comprise less than about 50 mg of satraplatin, such as an amount selected from about 25 mg, about 15 mg, about 10 mg, and about 5 mg
  • a unit dosage form of formulation B may comprise less than about 10 mg of satraplatin, such as an amount selected from about 5 mg, about 2 mg, about 1 mg and about 0.5 mg.
  • formulation A comprises an active ingredient X
  • formulation B comprises an active ingredient Y, wherein active ingredient Y may be different from active ingredient X.
  • formulation A does not contain active ingredient Y and, preferably, formulation B does not contain active ingredient X.
  • formulation A and formulation B have different pharmacological or pharmacokinetic properties.
  • active ingredient X is selected from a cytotoxic compound, a chemotherapeutie compound, a high potency compound, a compound with a narrow therapeutic index, and an orally available platinum complex
  • active ingredient Y is selected from a cytotoxic compound, a chemotherapeutie compound, an orally available platinum complex, a radiosensitizer, an anti-emetic, an anti-diarrheal, a high potency compound, a compound with a narrow therapeutic index, and a hormonal anti-cancer agent.
  • active ingredient X is satraplatin or a prodrug or metabolite thereof, e.g., wherein formulation A may comprise 5-75 mg of satraplatin.
  • each dose is individually removable from the kit or package.
  • the kit or package further comprises subunits comprising a plurality of unit dosage forms of formulation C, wherein formulation C may be different from each of formulations A and B.
  • formulation A, formulation B, and formulation C each comprise an active ingredient X, and the amount of active ingredient X in the unit dosage forms of each formulation A, B, and C, is different from the amount of active ingredient X in the unit dosage forms of either of the other two formulations.
  • formulation A comprises active ingredient X
  • formulation B comprises active ingredient Y
  • formulation C comprises active ingredient Z
  • each of active ingredients X, Y, and Z are different from the other two active ingredients (e.g., each of the three formulations comprises an active ingredient that is not present in either of the other two formulations).
  • any embodiment described herein may further comprise subunits comprising unit dosage forms of formulation C in an analogous manner to subunits of unit dosage forms comprising formulations A and/or B.
  • the package may comprise one or more further formulations, such as formulation D.
  • At least one subunit A is physically associated with at least one subunit B.
  • the unit dosage forms of formulation A and unit dosage forms of formulation B are arranged in a grid pattern such that each row is a dose and each column is a subunit.
  • the total number of doses in a kit or package is between 3 and 35, between 5 and 14, about 14, about 7, or about 5. Each dose may be designated with a day of the week or month, though not necessarily designated with consecutive days.
  • each dose may be designated with consecutive day numbers (Day 1, Day 2, etc.), dose numbers (Dose 1, Dose 2, etc.), time intervals indicating the number of hours that should elapse between administration of doses (6 h, 4 h, etc.), or more general temporal classifications such as "Morning”, “Evening”, “Breakfast”, “Lunch”, or “Dinner”, optionally comprising one or more further temporal designations such as "Monday morning” etc.
  • the doses may be designated in any appropriate manner, for example, coloring, labeling, printing, scoring, embossing, or other distinguishing features.
  • a package or kit of the invention may be labeled with information about the names of the active ingredient(s), the amount of active ingredient in each unit dosage form, or information or warnings about any of the active ingredients in the unit dosage forms of the package.
  • These designations or labels may be an integral part of the package added during the manufacturing process, or they may be added by the pharmacist or patient to customize the designation or label to the patient since, for example, some patients may start a variable-dose regimen on a Monday, while some may start the regimen on a Thursday.
  • the package may be used to administer a tapered dose.
  • formulations A and B are, for example, formulations of the same active ingredient in different dosages.
  • six unit dosage forms of both formulations A 4 and B 5 are included for the first day of administration, while by the fifth day, the number of unit dosages of formulation B 5 in each dose decreases such that there are no longer any unit dosage forms of formulation B, thereby lowering the overall dose of the active ingredient..
  • dose 1 may comprise, two unit dosage dose forms of formulation A and one unit dosage dose form of formulation B
  • dose 2 comprises one unit dosage form of formulation B but has no unit dosage forms of formulation A
  • dose 3 comprises two unit dose forms of formulation A and one unit dose form of formulation B, etc.. This could be accomplished by leaving spaces, akin to those illustrated in the tapered dose figure Ib, or by having placebos in the A subunits.
  • a package according to the invention might include fewer unit dosage forms of a formulation that induces drowsiness for a morning dose than are included in a dose that will be taken in the evening.
  • morning doses might include unit dosage forms of a formulation that comprises an active agent that counters drowsiness, while unit dosage forms of this formulation might be excluded from doses to be taken in the evening.
  • some subunits may have fewer unit dosage forms than other subunits in the package.
  • the kit or package may be of any shape, and the subunits comprising unit dosage forms arranged in any pattern, as long as the patient can readily determine which unit dosage forms are part of each dose.
  • the unit dosage forms may be arranged to form a circular, triangular, trapezoidal, hexagonal or other shape. In other embodiments, the shape may be three dimensional.
  • the kit or package is configured such that subunits can easily be added to or removed from the kit or package.
  • the kit or package may be circular.
  • each subunit 1 is a circular ring, wherein multiple subunits are concentric rings, and each dose 2 is a radial segment of the package.
  • FIG. 3 depicts yet another embodiment of the invention, wherein a kit is supplied as a partially filled template and comprises at least one subunit A 1 that is integral to the kit, multiple subunits A 1 being serially connected and integral to the kit, coupled to a plurality of serially connected compartments 6, wherein each compartment is capable of receiving a subunit B 1.
  • each column of the kit is a subunit 1 and each row is a dose 2, such that subunits B 1 added to the compartments increase the dose of the variable-dose therapeutic regimen, thereby allowing the dose to be customized for a patient.
  • each subunit contains an equal number of unit dosage forms.
  • the subunits A 1 and B 2 are arranged such that the unit dosage forms of formulation A 4 together with the unit dosage forms of formulation B 5 form a grid, wherein each column is a subunit 1 or 2 and each row is a dose 3 (or vice versa).
  • each subunit B 2 is a strip of blister packs, wherein each blister pack contains a single unit dosage form.
  • Compartments 6 may be any structure capable of receiving a subunit B 2, either reversibly or irreversibly, such as slots, openings, gaps, notches, cavities, or receptacles.
  • subunit B 2 strips can be added to the kit by sliding the strip into the slot 6.
  • the subunit B strip, and subunit A-compartment components may be supplied either separately or together and a pharmacist could fill a prescription by adding the appropriate number of subunit B strips to the kit to afford a package that contains a customized dose for a patient.
  • all of the compartments are empty, thereby providing a kit that contains only subunits A.
  • the invention in another aspect, relates to a kit or package for a variable-dose therapeutic regimen, as shown in Figure 4, comprising a plurality of serially connected compartments 6 and 7 in a template, including at least one compartment A 6, capable of receiving a subunit A 1 and at least one compartment B 7, capable of receiving a subunit B 2, wherein a dose 3 comprises a unit dosage form from each subunit of the kit , such that subunits A 1 and subunits B 2 added to the compartments increase the dose of the variable-dose therapeutic regimen, and wherein compartment(s) A 6 and compartment(s) B 7 may be the same or different.
  • a medicine filled blister strip having individually sealed spaced blisters is dropped down onto each blister strip cartridge base when a locking arm is in an open position and then is locked thereto when the locking arm is moved into a closed position, the locking arm including an open hold down frame for each individual blister, through which the blister is visually exposed, thereby locating the blister strip in operative assembly with the cartridge.
  • the cartridge also includes a pillbox with an identification card having information indicia, the card being attachable to the top. The information indicia is readable through slots in the top, floor, and dispensing frame floor, and from beneath the dispensing frame floor when the cartridge is functionally engaged with the dispensing frame.
  • a package may contain only subunit(s) A or only subunit(s) B rather than a combination of subunit(s) A and subunit(s) B. This situation may arise when a given number of subunit(s) A provides the appropriate amount of an active ingredient X for a customized dose for a patient.
  • the compartments are slots that are adapted to each receive a subunit and subunit(s) A 1 and/or B 2 are strips of blister packs that are adapted to each fit in a slot, as shown in Figure 4.
  • the package further comprises holes in the backing of the slots 8 such that a unit dosage form may be pushed out of the package without removing the subunit from the package.
  • the compartment component 6 and 7, subunits A 1, and subunits B 2 may be supplied either together or separately. A pharmacist filling a prescription for a variable-dose therapeutic regimen would add the appropriate number of subunit A 1 and subunit B 2 strips to the kit to afford a package that contains a customized dose for a patient.
  • subunit(s) A and/or subunit(s) B could be added by sliding the subunit strips 1 and/or 2 into a slot 6 or 7.
  • the subunits A 1 and B 2 and their corresponding compartments 6 and 7 may be differently dimensioned, for instance, such that subunits A 1 are too large to fit in compartments for subunits B 7, and, optionally, subunits B 2 are too small to be retained in compartments for subunits A 6.
  • a wide strip may be used for subunits A 1 and a narrow strip for subunits B 2.
  • compartments 6 and 7 have the same dimensions such that a compartment 6 or 7 is adapted to receive any of the subunits of the kit.
  • each dose is individually removable from the package, e.g., so that empty packaging can be removed after a dose has been taken, or so that a dose can be removed from the package so as to be more conveniently administered away from the patient's home, obviating any need to carry a complete, bulky package on short trips, for example.
  • a package may comprise a plurality of serially connected subunits A 1 and B 2 comprising at least one subunit A 1, itself comprising a plurality of unit dosage forms of formulation A 4, and at least one subunit B 2, itself comprising a plurality of unit dosage forms of formulation B 5, wherein a dose 3 comprises a unit dosage form from each subunit of the package and each subunit is removable from the package, such that the dose of the variable-dose therapeutic regimen decreases when units are removed, with the proviso that there is always at least one subunit A in the package, thereby allowing the dose to be customized for a patient.
  • the package is adapted, such as by scoring or perforation, such that each subunit and/or each dose is individually removable from the package.
  • Figure 5 shows an example of such a package, wherein each subunit A 1 or B 2 as well as each dose 3 is removable from the package due to scoring or perforations 9 arrayed over the package.
  • the terminal subunit A may be equipped with wells 15 and subunit(s) B may be equipped with plugs 16 and wells 15 that can be fixably inserted into the wells in a reversible or irreversible fashion.
  • Subunit(s) A 1 and subunit(s) B 2 may be supplied either separately or together.
  • a pharmacist could fill a prescription using a kit to assemble a package according to the invention using subunits as exemplified by any one of Figures 6 to 8 by inserting appendages 12, 14, or 16 into receptacles 11, 13, or 15.
  • Reversible attachment carries with it the advantage that the pharmacist can readily correct errors in assembling a package; irreversible attachment may be helpful in preventing inadvertent detachment of subunits by the patient, which may result in an undesirable change in the dose being administered to the patient.
  • each subunit 1 or 2 may be optionally equipped with appendages 12, 14, or 16 and receptacles 11, 13, or 15, respectively, thus allowing an infinite number of subunits to be associated with one another.
  • Other positioning means suitable to associate subunit(s) A with subunit(s) B may include clips, fastenings, sockets or locating appendages.
  • the package can be illustrated by Figure 9, wherein the terminal subunit A 1 is equipped with an adhesive or fastening material 17 and the subunit(s) B 2 is equipped with material 18 adapted to be affixed to 17.
  • the adhesive is applied during the manufacturing process and is protected with a removable cover that may be removed by the pharmacist to expose the adhesive.
  • the adhesive is supplied separately and is applied to the subunit(s) when the package is prepared.
  • the adhesive or fastening material 17 is selected from glue, tape, mushrooms, and hooks and the material adapted to be affixed to 18 is selected from glue, tape, cardboard, plastic, foil, mushrooms, and loops.
  • a pharmacist could provide a package by exposing the adhesive 17 on subunit(s) A and adhering subunit(s) A 1 to subunit(s) B 2. Again, the attachment could be made reversible or irreversible in certain of these embodiments.
  • kit can be illustrated by Figure 9, wherein the terminal subunit A 1 is equipped with a groove 17 that is adapted to receive a tongue and the terminal subunit B 2 is equipped with a tongue 18 that is adapted to fit into groove 17.
  • the kit can be illustrated by Figure 10, wherein each subunit 1 and 2 is equipped with protrusions 19, such that the subunits fit together in a manner similar to a jigsaw puzzle.
  • a kit exemplified by Figure 10 has the advantage that an unlimited number of subunits 1 and 2 can be associated with one another.
  • multiple subunits B may be brought into association by further adapting subunit B Io have the means comprised on subunit A 5 e.g., such that each such subunit has both "male” and "female” attachment parts.
  • the subunits A may be so associated in such a manner, and in yet other embodiments all subunits comprising the kit or package are so associated.
  • the package or the kit may include, comprise or be included in a child-resistant enclosure, system or solution.
  • suitable child-resistant packages are disclosed in US 6,412,636, US 6,047,829, and 6,230,893, which are incorporated herein by reference in their entirety. These containers are directed generally to a two-piece package for housing and dispensing a unit dose product. The product to be dispensed is contained on an internal slide card that is removably and lockably engaged within an outer sleeve.
  • the package provides a child resistant and user-friendly dosing means that can be opened and closed numerous times while in use, then disposed of when all the unit doses are exhausted.
  • a child-resistant container is the "Surepak" system from MeadWestvaco Healthcare Packaging which is a semi-rigid blister reclosable package that includes a fiberboard and plastic outer carton containing an affixed blister card.
  • the front of the blister card covers each tablet with a clear semi ⁇ rigid plastic and the back of the card is made of foil.
  • the package may be opened by pushing a finger through a hole located on the back of the outer carton, and pulling back on a trigger to release a latch while lifting one of the two tabs on the front of the outer carton, thereby exposing the blister card.
  • the invention relates to a method for assembling or preparing any one of the packages described above comprising determining the appropriate number of unit dosage forms of formulations A and B (or A, B, and C, etc.) to achieve a prescribed dose of a variable-dose therapeutic regimen, and adding or removing subunits from the package or kit so as to customize the dose of the variable-dose therapeutic regimen for a patient.
  • the subunits may be supplied in bulk as on a roll as shown in Figure 11 , a sheet as shown in Figure 12, concentric rings as shown in Figure 13, strips as shown in Figure 14, or in another pre-formed interconnection.
  • the subunits may be supplied as foil packs or blister packs on a roll, a sheet, concentric rings, strips, or other pre-formed interconnections.
  • Such bulk subunits or interconnected unit dosage forms may be adapted, such as with perforations, scores, or designations, to aid the partition of a subunit comprising an appropriate number of unit dosage forms.
  • the subunits may be supplied together with, or separate from, a package frame or template.
  • Subunits A and subunits B may be supplied in the same form (e.g., strips) or they may be supplied as two different forms (e.g., subunits A are integral to the • frame or template and subunits B are strips). In certain embodiments, subunits A and subunits B are available separately to accommodate separate manufacturing, supplying and ordering of each type of subunit.
  • the kit further comprises instructions for assembling the package. In certain embodiments, the assembly of a package may further comprise calculating the appropriate amount of active ingredient(s) required by a patient. Once the appropriate amount of active ingredient(s) has been calculated, the appropriate type and number of subunit(s) can be determined to achieve the appropriate dose of the variable-dose regimen for a patient.
  • kits disclosed herein different classes of subunits for a given formulation A and/or B are provided, each class with different number of unit dosage-forms of the given formulation, optionally with blank or placebo units. Such different classes of subunits would be advantageous to form a package the shown in Figure Ib.
  • the unit dosage-forms of the different formulations are provided loose in bulk, such as in a bottle, vessel, box or bag.
  • the kit of the instant invention may include a means to physically associate the unit dosage-forms, for example a medicine cartridge of US 6,082,544, or a paperboard blank as disclosed in US 5,954,202, together with instructions to form the customized dose by inserting in such cartridge or paperboard blank, the appropriate number of individual unit dosage-forms of formulation A and/or B so as to form the customized dose.
  • a means to physically associate the unit dosage-forms for example a medicine cartridge of US 6,082,544, or a paperboard blank as disclosed in US 5,954,202, together with instructions to form the customized dose by inserting in such cartridge or paperboard blank, the appropriate number of individual unit dosage-forms of formulation A and/or B so as to form the customized dose.
  • the invention further relates to a method for treating a patient suffering from a disease or condition, comprising, determining the appropriate dose of a variable- dose therapeutic regimen, prescribing a customized dose of the variable-dose therapeutic regimen, and instructing the patient to consume a unit dosage form from each subunit of the package at predetermined intervals.
  • the disease or condition is selected from cancer, hypertension, hypothyroidism, heart- related ailments, and depression.
  • the disease or condition is a cancer selected from liver, stomach, colon, breast, pancreatic, skin, cervical, ovarian, testicular, lung, head and neck, prostate, hormone resistant prostate, small cell lung, and metastases thereof.
  • the invention relates to combination therapy, wherein a variable-dose therapeutic regimen package is co ⁇ administered with another therapeutic agent, or with another therapeutic regime such as radiotherapy.
  • kits or packages may be associated with at least one other kit or package such that the kit or packages are dispensed to a pharmacist or patient as a combination kit or package.
  • chemotherapeutic or “chemotherapy” is art-recognized and includes compounds that are selectively toxic to the causative agent of the disease, such as cancer cells.
  • chemotherapeutic compounds include, but are not limited to, Iressa (gefitinib), Tarceva (erlotinib HCl), Xeloda (capecitabine), mitoxantrone, estramustine phosphate, etoposide, and doxorubicin.
  • high potency herein is defined as a compound that has a therapeutic effect at a very low dose, e.g., less than a few milligrams, and overdose of such a compound by a small fraction can lead to severe adverse or toxic reactions.
  • high potency compounds or those having a narrow therapeutic index include, but are not limited to, levothyroxine sodium, warfarin, paclitaxel, haloperidol, pimozide, diflucortolone, ropinirole hydrochloride, and betamethasone.
  • co-administer refers to at least two therapeutic agents that are administered as part of a single therapeutic regimen. Such combination treatment may be achieved by way of the simultaneous, sequential, or separate dosing of the individual components of the treatment.
  • cytotoxic is art-recognized and includes any compound that is directly toxic to cells, preventing their reproduction or growth.
  • cytotoxic compounds include, but are not limited to, irinotecan, melphalan, chlorambucil, vincristine, vinblastine, azathioprine, cyclophosphamide, methotrexate, and mitomycin-C.
  • hormoneal anti-cancer agent includes, but is not limited to, leuprolide, goserelin, flutamide, bicalutamide, nilutamide, and ketoconazole.
  • narrow therapeutic index is defined to describe a compound, whose optimal therapeutic effect of which is achieved by precise dosing of the compound to suit a particular patient.
  • Factors that can influence the suitability of an optimal dose for such a compound can include the size, weight, age, condition, sex or other factors of the patient. For example, administration of too little of such a compound for a heavy patient may not cause a therapeutic effect, while administration of too much of such a compound may cause undesirable side effects.
  • radiosensitizer is art-recognized and includes any compound with the ability to increase tissue radiosensitivity.
  • radiosensitizers include, but are not limited to, 5-fluorouracil, topotecan, and tirapazamine
  • anti-emetics include, but are not limited to, ondansetron, granisetron, dolasetron, diphenhydramine, hydroxyzine, metoclopramide, lorazepam, (alprazolam), haloperidol, droperidol, dronabinol, dexamethasone, prochlorperazine, and tropisetron.
  • anti-diarrheals examples include, but are not limited to, bismuth subsalicylate, absorbent clay, calcium polycarbophil, and loperamide.
  • kit is herein defined as a set of parts or a subset thereof that may be used to assemble a package. This may include, for example, subunits A, B, and/or C (or unit dosage forms of formulations A, B and/or C, etc.) supplied to a pharmacist in bulk quantities, instructions for the assembly of a package from a kit, and any label(s) or adhesives that are appropriate for a given package.
  • Heart-related ailments includes any chronic or acute pathological event involving the heart and/or associated tissue (e.g., the pericardium, aorta and other associated blood vessels), including ischemia-reperfusion injury; congestive heart failure; cardiac arrest; myocardial infarction; cardiotoxicity caused by compounds such as drugs (e.g., doxorubicin, herceptin, thioridazine and cisapride); cardiac damage due to parasitic infection (bacteria, fungi, rickettsiae, and viruses, e.g., syphilis, chronic Trypanosoma cruzi infection); fulminant cardiac amyloidosis; heart surgery; heart transplantation; traumatic cardiac injury (e.g., penetrating or blunt cardiac injury, and aortic valve rupture), surgical repair of a thoracic aortic aneurysm; a suprarenal aortic aneurysm; cardiogenic shock due to myocardial infarction
  • Instruction(s) as used herein means a product label and/or documents describing relevant materials or methodologies pertaining to assembly, preparation, or use of a kit or packaged pharmaceutical. These materials may include any combination of the following: background information, steps or procedures to follow, list of components, proposed dosages, warnings regarding possible side effects, instructions for administering the drug, technical support, and any other related documents.
  • Metabolites as used herein is art-recognized and includes any substance derived from an active ingredient by any physical, chemical, biological, or biochemical process in the body or a cell after the active ingredient is administered. Metabolites may be formed outside of the target cell (such as in the GI tract) or may be formed by synthetic reactions from suitable starting material and administered directly to a cell or body.
  • JMl 18 may be synthesized according to the method disclosed in EP 0147926, GB 2060615, and US 4329299, US 6350737, US 6503943, EP 1186610, the contents of which are hereby incorporated by reference in their entirety, or may be formed via biotransformation of JM216 in a separate fermentation step.
  • the term “orally available” as used herein is art-recognized and includes any agent that has biological, physiological, pharmacological, therapeutic, medical, or clinically significant activity when administered orally.
  • platinum complexes include, but are not limited to satraplatin (JM216), JMl 18, JM383, or a pharmaceutically acceptable salt, isomer, or prodrug thereof, as well as platinum complexes disclosed in EP 0147926, US 5072011, US 5244919, US 6,503,943, US 6,350,737, and US 5519155, which are all hereby incorporated by reference in their entirety.
  • Raynaud, et al. (1996 Cancer Chemother. Pharmacol. 38: 155-162) shows exemplary metabolites of satraplatin, and is hereby incorporated in its entirety by reference.
  • prophylactic or therapeutic treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If the composition is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, (i.e., it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
  • the unwanted condition e.g., disease or other unwanted state of the host animal
  • preventing is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition the intent of which is to reduce the frequency of, or delay the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition.
  • a condition such as a local recurrence (e.g., pain)
  • a disease such as cancer
  • a syndrome complex such as heart failure or any other medical condition
  • prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, and/or delaying disease progression and/or improving the quality of patient life, e.g., by a statistically and/or clinically significant amount.
  • Prevention of an infection includes, for example, reducing the number of diagnoses of the infection in a treated population versus an untreated control population, and/or delaying the onset of symptoms of the infection in a treated population versus an untreated control population.
  • Prevention of pain includes, for example, reducing the magnitude of, or alternatively delaying, pain sensations experienced by subjects in a treated population versus an untreated control population.
  • prodrug encompasses compounds that, under physiological conditions, are converted into therapeutically active agents.
  • a common method for making a prodrug is to include selected moieties that are hydrolyzed under physiological conditions to reveal the desired molecule.
  • the prodrug is converted by an enzymatic activity of the host animal.
  • JM518 may be considered a prodrug of JMl 18, as JMl 18 (a subject active ingredient) is formed by metabolism of JM518.
  • JM216 may also be considered a prodrug of JMl 18.
  • sachet refers to a small bag or packet containing a dose of medicine.
  • template refers to any frame, scaffold, skeleton, basis, construction, arrangement, configuration, structure, or support that is adapted to accommodate unit dosage forms or subunits as described herein, especially in a predetermined configuration.
  • Non-limiting examples of a template are given by a paperboard blank of US 5,954,202, a medicine cartridge or US 6,082,544 and a connected-compartment 6 of Figure 4 herein.
  • a “therapeutically effective amount” of a compound refers to an amount of the compound(s) in a preparation which, when administered as part of a desired dosage regimen (to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, e.g., at a reasonable benefit/risk ratio applicable to any medical treatment.
  • a “unit dosage form” is defined herein as a discrete unit that comprises a formulation of a therapeutic agent.
  • suitable unit dosage forms include, but are not limited to tablets, capsules, or gelcaps.
  • “Variable-dose therapeutic regimen” as used herein refers to a regimen wherein the dose is adjusted based on the needs of the individual patient to which the medication is to be prescribed and/or administered. Some factors that may be used in the determination of the dose include, but are not limited to, age, body weight, body surface area, and the severity of the disease or medical condition.
  • Unit dosage forms prepared as described herein can be administered in various forms, depending on the disorder to be treated and the age, condition, and body weight of the patient, as is well known in the art.
  • the compounds may be formulated as tablets, capsules, or gelcaps; or for parenteral administration, they may be formulated as suppositories.
  • These formulations can be prepared by conventional means, and, if desired, the active ingredient may be mixed with any conventional additive, such as an excipient, a binder, a disintegrating agent, a lubricant, a corrigent, a solubilizing agent, a suspension aid, an emulsifying agent, or a coating agent.
  • a daily dosage of from 0.01 to 2000 mg of the compound is recommended for an adult human patient, and this may be administered in a single dose or divided into a plurality of doses, preferably forming a patient customized dose.
  • the precise time of administration and/or amount of the unit dosage form that will yield the most effective results in terms of efficacy of treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a particular compound, physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), route of administration, etc.
  • physiological condition of the patient including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication
  • route of administration etc.
  • the above guidelines can be used as the basis for fine-tuning the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those ligands, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable carrier means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ or portion of the body, to another organ or portion of the body.
  • a pharmaceutically acceptable material, composition or vehicle such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ or portion of the body, to another organ or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum
  • pharmaceutically acceptable salts refers to the relatively non ⁇ toxic, inorganic and organic acid addition salts of the unit dosage form(s). These salts can be prepared in situ during the final isolation and purification of the unit dosage form(s), or by separately reacting a purified unit dosage form(s) in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts, and the like.
  • sulfate bisulfate
  • phosphate nitrate
  • acetate valerate
  • oleate palmitate
  • stearate laurate
  • benzoate lactate
  • phosphate tosylate
  • citrate maleate
  • fumarate succinate
  • tartrate naphthylate
  • mesylate glucoheptonate
  • lactobionate lactobionate
  • laurylsulphonate salts and the like.
  • the unit dosage forms useful in the methods of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases.
  • pharmaceutically acceptable salts refers to the relatively non-toxic inorganic and organic base addition salts of a unit dosage form(s). These salts can likewise be prepared in situ during the final isolation and purification of the unit dosage form(s), or by separately reacting the purified unit dosage form(s) in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine.
  • Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like.
  • Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., supra).
  • wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring, and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, burylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
  • water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, and the like
  • oil-soluble antioxidants such as ascorbyl palmitate, burylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT
  • Formulations useful in the methods of the present invention include those suitable for oral, rectal, vaginal, and/or parenteral administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
  • the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated and the particular mode of administration.
  • the amount of active ingredient which may be combined with a pharmaceutically acceptable carrier to produce a single dosage form will generally be that amount of the compound which produces the desired therapeutic effect. It should be understood that in certain embodiments the amount of active ingredient required to produce the desired therapeutic effect may be lower when used in combination with another active ingredient.
  • the amount that produces a desired therapeutic effect is determined in the context of a combination therapy contemplated or provided by a package of the instant invention. Generally, out of one hundred per cent, the amount of active ingredient will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
  • Methods of preparing these formulations or compositions include the step of bringing into association a therapeutic agent(s) with the carrier and, optionally, one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association a ligand with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • Formulations suitable for oral administration may be in the form of capsules, sachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), each containing a predetermined amount of a unit dosage form(s) as an active ingredient.
  • the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acet
  • the pharmaceutical compositions may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugars, as well as high molecular weight polyethylene glycols, and the like.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine a mixture of the powdered peptide or peptidomimetic moistened with an inert liquid diluent.
  • Tablets, and other solid dosage forms may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes, and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
  • opacifying agents include polymeric substances and waxes.
  • the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.
  • Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more unit dosage form(s) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
  • suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents.
  • Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium
  • the unit dosage forms(s) of the present invention are administered as pharmaceuticals to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
  • agents may be given orally, parenterally, or rectally. They are of course given by forms suitable for each administration route. For example, orally they are administered in tablet or capsule form, and rectally they are administered by suppository. Oral administration is preferred.
  • systemic administration means the administration of a ligand, drug, or other material other than directly into the central nervous system, such that it enters the patient's system and thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
  • the unit dosage form(s), which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
  • Actual dosage levels of the active ingredients in the pharmaceutical compositions and or numbers of formulations A and/or B included in the packages or kits of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

L'invention se réfère á un emballage et des kits pour la distribution et/ou l'administration de produits pharmaceutiques, en particulier pour la distribution et/ou l'administration de combinaisons de différentes formulations.
EP05789206A 2004-07-14 2005-07-13 Système d'emballage à dose variable Withdrawn EP1781230A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58773504P 2004-07-14 2004-07-14
PCT/US2005/024761 WO2006019760A1 (fr) 2004-07-14 2005-07-13 Système d'emballage à dose variable

Publications (1)

Publication Number Publication Date
EP1781230A1 true EP1781230A1 (fr) 2007-05-09

Family

ID=35414686

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05789206A Withdrawn EP1781230A1 (fr) 2004-07-14 2005-07-13 Système d'emballage à dose variable

Country Status (6)

Country Link
US (1) US20080272022A1 (fr)
EP (1) EP1781230A1 (fr)
JP (1) JP2008506463A (fr)
AU (1) AU2005275205A1 (fr)
CA (1) CA2573762A1 (fr)
WO (1) WO2006019760A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2618520C (fr) * 2005-08-25 2015-01-27 Oriel Therapeutics, Inc. Systemes contenant un medicament avec sticks et kits associes, inhalateurs a poudre anhydre, et procedes correspondants
ES2578616T3 (es) * 2007-05-04 2016-07-28 Unit Dose Pack B.V. Método para la fijación de una tarjeta de información a un artículo envasado en un blíster, una tarjeta de información y un sistema que usa la tarjeta de información
WO2009087553A1 (fr) * 2008-01-02 2009-07-16 Aurobindo Pharma Limited Kits pour l'administration de bisphosphonates
US8136666B2 (en) * 2009-02-27 2012-03-20 Goldman Kenneth N Daily dose personal pill dispenser
US20110193333A1 (en) * 2010-02-11 2011-08-11 Parrish Delmer H Medicine administration card and related method of use
US20130015095A1 (en) * 2011-07-14 2013-01-17 Omnicare Inc. Administration methods and packagings for dosage units
EP2962578A1 (fr) * 2014-06-30 2016-01-06 Richard Hubertus Verheesen Procédé de fourniture d'une pluralité de portions nutritives à un utilisateur et produit d'emballage
WO2017044628A2 (fr) * 2015-09-08 2017-03-16 Accredo Health Group, Inc. Système de distribution de médicaments
GB2589635B (en) * 2019-12-06 2021-12-01 Merxin Ltd Elongate form medicament carrier and medicament dispenser
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2103694A1 (de) * 1971-01-27 1972-08-17 Asta Werke Ag Chem Fab Packung für Tabletten, Dragees, Kapseln od. dgl
GB1601885A (en) * 1978-05-30 1981-11-04 Sterwin Ag Packaging
ZA805101B (en) * 1979-08-23 1981-08-26 Johnson Matthey Co Ltd Compositions containing platinium
DE3623331A1 (de) * 1986-07-11 1988-01-21 Hoechst Ag Konfektionspackungen, enthaltend arzneimittelkombinationen fuer zeitlich abgestufte anwendung
SE465317B (sv) * 1986-09-25 1991-08-26 Astra Laekemedel Ab Laekemedelsfoerpackning och kombinationsfoerpackning foer laekemedel samt anvaendning av laekemedelsfoerpackningar foer framstaellning av en kombinationsfoerpackning
US5072011A (en) * 1988-02-02 1991-12-10 Johnson Matthey, Inc. Pt(IV) complexes
US5244919A (en) * 1988-02-02 1993-09-14 Johnson Matthey, Inc. Pt(IV) complexes as anti-tumor agents
SE460760B (sv) * 1988-03-01 1989-11-20 Astra Ab Hanteringsanordning foer dosenheter av laekemedel, foerfarande foer dess framstaellning och medel foer genomfoerande av foerfarandet
GB9408218D0 (en) * 1994-04-26 1994-06-15 Johnson Matthey Plc Improvements in platinum complexes
US5954202A (en) * 1996-06-28 1999-09-21 Westvaco Corporation Paperboard blank for a self-contained, reclosable package
CZ288912B6 (cs) * 1998-05-27 2001-09-12 Lachema, A. S. Komplex platiny v oxidačním čísle IV, způsob přípravy tohoto komplexu, tento komplex jako léčivo a farmaceutická kompozice tento komplex obsahující
CZ288406B6 (en) * 1998-05-27 2001-06-13 Lachema Np Platinum complex of oxidation number II, process for preparing such complex, the complex functioning as medicament and pharmaceutical composition in which the complex is comprised
US6047829A (en) * 1998-09-18 2000-04-11 Westvaco Corporation Unit dose packaging system (UDPS) having a child resistant locking feature
US6082544A (en) * 1999-02-01 2000-07-04 Artromick International, Inc. Medicine unit dose dispensing system and method
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
DE29913195U1 (de) * 1999-07-28 2000-02-10 Kugler Astrid Kombinationspackung für Medikamente
US6230893B1 (en) * 2000-02-11 2001-05-15 Westvaco Corporation Unit dose packaging system (udps) having a child resistant locking feature
WO2003020200A2 (fr) * 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. Nouveau compose pharmaceutique et procedes de fabrication et d'utilisation de ce compose
US6412636B1 (en) * 2001-05-21 2002-07-02 Westvaco Corporation Unit dose packaging system with child resistance and senior friendly features
GB0129176D0 (en) * 2001-12-06 2002-01-23 Dca Design Int Ltd Improvements in and realting to a medicament cartridge assembly

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006019760A1 *

Also Published As

Publication number Publication date
JP2008506463A (ja) 2008-03-06
AU2005275205A1 (en) 2006-02-23
CA2573762A1 (fr) 2006-02-23
WO2006019760A1 (fr) 2006-02-23
US20080272022A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
US20080272022A1 (en) Variable-Dose Packaging System
ES2182729T3 (es) Envase de tiras.
ES2339967T3 (es) Paquete de tabletas resistente a los niños.
US7150355B2 (en) Case with pill receiving sleeves for storing and dispensing pills
US6077530A (en) Analgesic dosage units for coordinated administration
ES2882956T3 (es) Método para proporcionar una terapia de pirfenidona a un paciente
US4958736A (en) Package for oral contraceptive tablet
US10314766B2 (en) Medication packaging and dose regimen system
JPH0811589B2 (ja) 暦日式ピル・ディスペンサ−
US10780022B2 (en) Medication packaging and dose regimen system
PL204431B1 (pl) Opakowanie środka leczniczego zwiększające zdyscyplinowanie pacjenta podczas leczenia eradykacyjnego schorzeń o podłożu drobnoustrojowym
PT1978912E (pt) Embalagem para produtos medicamentosos e equivalente
JPH0349763A (ja) 薬物摂取のための表示装置
JP2014529457A (ja) 患者コンプライアンス用ブリスターパッケージ
JP5588881B2 (ja) 用量設定パッケージ
RU94457U1 (ru) Упаковка суточной дозы лекарственных препаратов перорального применения для комплексной медикаментозной терапии (варианты) и упаковка лекарственных препаратов перорального применения для курса комплексной медикаментозной терапии
KR20230156952A (ko) 약제 투여 시스템
CN2516476Y (zh) 抗结核组合药包装板
JPS62109754A (ja) 薬袋

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHAH, HEMANSHU, S.

Inventor name: KULKARNI, SHIRISHKUMAR, B.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100202